Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Efficacy and Safety of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults with Chronic Hepatitis C Virus Genotypes 1-6 in Brazil.

< BACK TO ARCHIVE


2020 Sep 16


Ann Hepatol


http://www.ncbi.nlm.nih.gov/pubmed/32949786?dopt=Abstract

Efficacy and Safety of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults with Chronic Hepatitis C Virus Genotypes 1-6 in Brazil.

Authors

Efficacy and Safety of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults with Chronic Hepatitis C Virus Genotypes 1-6 in Brazil.
Peribañez-Gonzalez M, Cheinquer H, Rodrigues L, Lima M P, Álvares-da-Silva M R, Madruga J, Parise E R, Pessoa M G, Furtado J, Villanova M, Ferreira A, Mazzoleni F, Nascimento E, Silva G F, Fredrick L, Krishnan P, Burroughs M, Reuter T
Ann Hepatol. 2020 Sep 16.
PMID: 32949786.

Abstract

Glecaprevir/pibrentasvir is a highly effective and well tolerated treatment for hepatitis C infection. Brazilian patients were not included in the original development studies for glecaprevir/pibrentasvir. This study aimed to assess safety and efficacy of glecaprevir/pibrentasvir in treatment-naïve Brazilian adults without cirrhosis or with compensated cirrhosis.
Read This Paper